Zim laboratories has received regulatory approval from the Dubai Multi Commodities Centre Authority (DMCC Authority) for the closure of its step-down subsidiary ZIM Laboratories Middle East DMCC (ZIM DMCC), effective February 23, 2026. The company announced this development through a regulatory filing to the stock exchanges, marking the completion of a key regulatory milestone in the subsidiary closure process.

Regulatory Approval Details

The DMCC Authority has formally approved the dissolution of ZIM DMCC, a step-down subsidiary of ZIM Laboratories Limited. This approval represents the final regulatory clearance required for the subsidiary's closure, which was initially approved by the company's Board of Directors.

Timeline of Events

The closure process began with the company's Board of Directors approving the step-down subsidiary's closure on August 7, 2025. The company had disclosed this board approval to the stock exchanges as part of its regulatory compliance obligations. The recent DMCC Authority approval represents the culmination of this closure process, providing the necessary regulatory clearance for the subsidiary's dissolution.

Compliance and Disclosure

ZIM Laboratories has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed both BSE Limited and the National Stock Exchange of India Limited about the DMCC Authority's approval through formal intimation dated February 23, 2026.

The regulatory filing was signed by Piyush Nikhade, Company Secretary and Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements. This disclosure maintains transparency with stakeholders regarding the subsidiary's closure and its regulatory approval status.

ZIM Laboratories Limited has announced that ACUITE Ratings & Research Limited has reaffirmed the credit ratings on the company's bank facilities. The pharmaceutical company disclosed this development to the stock exchanges on February 17, 2026, in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Credit Rating Details

ACUITE Ratings & Research Limited has reaffirmed ratings across two categories of bank facilities for ZIM Laboratories. The rating agency maintained its assessment of the company's creditworthiness across both long-term and short-term financial instruments.

Regulatory Compliance

The company communicated this rating reaffirmation to both BSE Limited and National Stock Exchange of India Limited through a formal intimation letter. ZIM Laboratories trades on BSE with scrip code 541400 and on NSE with the symbol ZIMLAB. The disclosure was signed by Piyush Nikhade, Company Secretary and Compliance Officer, ensuring adherence to regulatory requirements.

Company Operations

ZIM Laboratories operates with its manufacturing facility located at B-21/22, MIDC Area, Kalmeshwar in Nagpur district, Maharashtra. The company's registered office is situated at Sadoday Gyan, Nelson Square, Nagpur. As a pharmaceutical company, ZIM Laboratories focuses on innovation in medicine, as reflected in its tagline "ZeaL & Innovation in Medicine."